Research includes studies designed to overcome
barriers to living donation and in-home treatment among African
American and Spanish-speaking Mexican American patients
DENVER and PHILADELPHIA, Nov. 2, 2023
/PRNewswire/ -- DaVita Clinical Research (DCR), a wholly owned
subsidiary of DaVita Inc., is presenting the findings of five new
research projects at the American Society of Nephrology (ASN)'s
annual "Kidney Week," which is currently underway in Philadelphia. The studies are focused on
driving health equity and reducing hospitalizations, among other
outcomes.
The following research will be presented during the event:
- Sociodemographic Barriers to Interest and Pursuit of Living
Donation Among ESKD Patients
- Increasing Home Dialysis Among Spanish-Speaking Mexican
American Patients: Challenges and Opportunities
- Barriers and Opportunities to Increase Home Dialysis among
African American Patients
- Managed Care Program Improves Hospitalization Rate in ESKD
Patients
- Comparative Effectiveness of Cinacalcet Delivered Daily at
Home Versus Three Times Weekly In-Center
"DaVita is committed to improving patient care, which informs
the projects we pursue – from our study showing the link between
enrollment in managed care programs and reduced hospitalizations,
to our work identifying the socio-cultural barriers that hinder
adoption of alternative dialysis therapies," said Dr. Steven Brunelli, DaVita vice president of health
analytics and insights. "As we strive to increase kidney
transplantation and expand adoption of in-home dialysis among the
individuals we serve, this research is designed to help inform
broader industry solutions that can benefit all patients with
kidney disease."
DaVita's vice president of medical affairs, Dr. Unini Odama,
will present on DaVita's research designed to increase home
dialysis among African American patients during the session titled
"Navigating a Path to Diversity and Equity in Kidney Health,"
taking place Friday, Nov. 3, at
5:30 p.m. ET in room 107 of the
Pennsylvania Convention
Center.
In addition to spearheading the research being presented, DCR
continues to expand the Chronic Kidney Disease and Rare Disease
Network (CKD-RDN), which the company announced last year at
Kidney Week. The network, which includes more than 200 physicians
and the expertise of five mentor research physicians, has yielded
strong collaboration with the pharmaceutical industry, including
driving advancements for conditions such as IgA Nephropathy, FSGS,
Alport Syndrome, and other rare kidney diseases. To learn more
about the CKD-RDN please click here, or stop by booth #1004 to meet
with DCR representatives.
ASN will also make a virtual experience available
at https://www.asn-online.org/kidneyweek. Content, including
posters and abstracts, will be available online.
DaVita will share updates throughout the meeting on X (formerly
Twitter) on @DaVitaDoc and @DaVitaResearch, and will join the
online conversation using #KidneyWk. To learn more about DCR,
visit www.DaVitaClinicalResearch.com.
About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly-owned subsidiary of
DaVita Inc., is the research arm of DaVita. DCR innovates through
retrospective research aimed at improving clinical outcomes. DCR
assists pharmaceutical and medical device companies in the design,
recruitment and completion of clinical trials using its renal
research site network. To learn more about DCR,
visit DaVitaClinicalResearch.com.
About DaVita
DaVita (NYSE: DVA) is a health care provider
focused on transforming care delivery to improve quality of life
for patients globally. The company is one of the largest providers
of kidney care services in the U.S. and has been a leader in
clinical quality and innovation for more than 20 years.
DaVita cares for patients at every stage and setting along
their kidney health journey—from slowing the progression of kidney
disease to helping to support transplantation, from acute hospital
care to dialysis at home. As of June 30,
2023, DaVita served approximately 201,000
patients at 2,703 outpatient dialysis centers in the United States. The company also operated
353 outpatient dialysis centers in 11 other countries
worldwide. DaVita has reduced hospitalizations,
improved mortality, and worked collaboratively to propel the kidney
care industry to adopt an equitable and high-quality standard of
care for all patients, everywhere. To learn more, visit
DaVita.com/About.
Contact: Georgina Rupp,
newsroom@davita.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/davita-unveils-new-research-to-drive-health-equity-and-improve-care-quality-during-annual-american-society-of-nephrology-meeting-301976144.html
SOURCE DaVita